Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Reference21 articles.
1. European Commission. Communication from the commission to the European parliament, the council, the European economic and social committee and the committee of the regions on rare diseases: Europe's challenges. European Commission
[online]
, (2008).
2. Stolk, P., Willemen, M. J. C & Leufkens, H. G. M. Rare essentials: drugs for rare diseases as essential medicines. Bull. World Health Organ. 84, 745–751 (2006).
3. Aymé, S. EUGLOREH project: the status of health in the European Union: towards a healthier Europe: full report. 5.15. Rare Diseases. EUGLOREH 2007
[online]
, (2007).
4. Heemstra, H. E., de Vrueh, R. L., van Weely, S., Büller, H. A. & Leufkens, H. G. Predictors of orphan drug approval in the European Union. Eur. J. Clin. Pharmacol. 64, 545–552 (2008).
5. Haffner, M., Torrent-Farnell, J. & Maher, P. D. Does orphan drug legislation really answer the needs of patients? Lancet 371, 2041–2044 (2008).
Cited by
103 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献